17 April 2022 - Under the changes announced today, an additional 71,000 Australians will have access to continuous glucose monitoring and flash glucose monitoring devices under the National Diabetes Support Scheme from 1 July 2022 for a maximum of $32.50 each month, equivalent to the cost they would already be incurring when using blood glucose test strips.

From next month, Australians with prostate cancer will have access to Erlyand (apalutamide), which will be listed on the PBS for the first time for the treatment of people with non-metastatic castration resistant prostate cancer.

Empliciti (elotuzumab) will also be listed on the PBS for the first time for the treatment of relapsed and/or refractory multiple myeloma for use in combination with medicines lenalidomide and dexamethasone.

Read Liberal Party press release